Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0152031 (swollen joints)
 535 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ninety-five patients with ankylosing spondylitis received either sulphasalazine (less than or equal to 3 g/day) or placebo for 24 weeks. The patients who received sulphasalazine showed significantly improved clinical parameters [duration of morning stiffness (p less than 0.05), the number of painful and swollen joints (less than 0.05)] and laboratory parameters [erythrocyte sedimentation rate (p less than 0.001), haptoglobin (p less than 0.05), IgG (p less than 0.05), IgA (p less than 0.001), IgM (p less than 0.05)]. No statistically significant differences were seen in the patients receiving placebo. The results suggest that sulphasalazine is effective for the treatment of patients with ankylosing spondylitis. In these patients, there was also a diminution of the daily dosage of nonsteroidal antiinflammatory drugs. In the majority of patients, clinical and laboratory improvements were expressed more pronouncedly in the peripheral form of ankylosing spondylitis than in the axial form, but statistically no significant differences were found between the two groups.
 ...
PMID:[Sulfasalazine in the treatment of ankylosing spondylitis]. 197 12

The purpose of the study was the evaluation of the effects of the combined therapy and non steroidal anti-inflammatory drugs on the acute phase reactants and clinical symptoms in patients with rheumatoid arthritis. The acute phase reactants that were observed were sedimentation of erythrocytes, C-reactive protein, haptoglobin and fibrinogen, while the clinical parameters that were observed were the number of swollen joints and the number of joints sensitive to the pressure. All the parameters were evaluated before the therapy initiation, there and six months after the therapy was finished. The treatment involved 80 patients with rheumatoid arthritis separated into three groups depending on the therapy applied: Group A (n = 29) received gold salts, sulphasalazine and tenoxicam, Group B (n = 25) received gold salts, sulphasalazine and indometacin, and Group C (n = 26) received gold salts, chloroquine and piroxicam. The results of our examination showed statistically significant descrease in value of acute phase reactants and of clinical indicators after the therapy carried out in each of the patient groups, while the values between the groups were of no statistical significance.
 ...
PMID:[Effect of combination therapy and nonsteroidal antirheumatic agents on acute phase reactants in patients with rheumatoid arthritis]. 1155 14